Mishcon de Reya page structure
Site header
Main menu
Main content section

Mishcon de Reya team advises Glamorous AI in sale

Posted on 30 November 2021

Technology client Glamorous AI has been acquired by X- Chem with Mishcon de Reya acting for the founders and investor sellers.

Glamorous AI is the developer of an artificial intelligence-based drug discovery platform. The company's platform specializes in the research of medicines using its proprietary artificial intelligence platform RosalindAI , integrated with cutting edge biology and chemistry. Its sale will offer several advantages for customers, including accelerating the discovery of new medicines and continuing to develop leading AI solutions for drug discovery.

Noor Shaker, CEO of Glamorous AI, commented: “X-Chem generates billions of high-quality data points with its DNA-encoded library (DEL) platform, and we provide the capability to build the best AI to unlock the power of those data. It is when such large datasets come together with a powerful technology like AI that transformation happens. This aligns very well with our vision to democratise access to AI and to provide a fully integrated service for the biopharma industry.”

Partner Charlie Fletcher, Managing Associate Daniel Smith and Associate Harriet Chang of Mishcon de Reya's Corporate team advised Glamorous AI on their sale.

Daniel said: “We are delighted to have supported the founders of Glamorous AI on their successful sale of the company to X-Chem. We are seeing a significant rise in acquisitions of companies that comprehensively utilise AI on their platforms and we expect this market activity to only increase further.”

Disclaimer: This deal took place in 2021when the deal team were at Taylor Vinters LLP, which merged with Mishcon de Reya in January 2023.

How can we help you?

How can we help you?

Subscribe: I'd like to keep in touch

If your enquiry is urgent please call +44 20 3321 7000

Crisis Hotline

I'm a client

I'm looking for advice

Something else